Biologics for Ankylosing Spondylitis

Ankylosing spondylitis, or AS, has a real talent for making basic human activities feel oddly ambitious. Getting out of bed? Olympic event. Turning your neck to back out of the driveway? High-risk maneuver. Sitting too long, standing too long, sleeping too long, not sleeping enoughAS can turn all of it into a running argument between your spine and your plans.

That is where biologics come in. These medications are not ordinary pain relievers, and they are definitely not the “just stretch more” advice your least helpful relative keeps offering. Biologics are targeted drugs designed to calm specific immune system signals that drive inflammation in ankylosing spondylitis. For many people, they can reduce pain and stiffness, improve mobility, and make daily life feel less like a negotiation with concrete.

If you are trying to understand how biologics for ankylosing spondylitis work, who may need them, and what to expect before the first injection or infusion, this guide walks through the big picture in plain English.

What are biologics for ankylosing spondylitis?

Biologics are advanced medications made from living cells or biologic processes. In AS, they are used to target parts of the immune system that are sending too many inflammatory signals. Think of them as less of a blanket attack and more of a “please stop pressing the fire alarm” message to the immune pathways causing trouble.

That matters because ankylosing spondylitis is not just routine back pain. It is a chronic inflammatory disease that mainly affects the spine and sacroiliac joints, though it can also involve the hips, shoulders, ribs, eyes, skin, and gut. Over time, uncontrolled inflammation can limit movement and contribute to structural damage. Biologics do not cure AS, but they can be an important part of controlling disease activity and protecting quality of life.

When do doctors usually recommend biologics?

Biologics are usually not the first medication someone tries. In most cases, treatment starts with nonsteroidal anti-inflammatory drugs, or NSAIDs, along with exercise and physical therapy. If symptoms stay active despite that, a rheumatologist may recommend stepping up to a biologic.

Biologics may be considered when:

• Back pain and morning stiffness remain significant despite NSAIDs
• Inflammation is interfering with sleep, work, mobility, or exercise
• The disease is active enough that symptom control is not good enough with basic treatment
• There are related issues such as uveitis, psoriasis, or inflammatory bowel disease that may affect drug choice
• Traditional non-biologic medications are not appropriate or are not doing enough

In other words, biologics usually enter the chat when AS is still running the show.

Main types of biologics used for AS

There are two main biologic families used for ankylosing spondylitis in the United States right now.

1. TNF inhibitors

These block tumor necrosis factor, or TNF, a major inflammatory protein involved in AS. TNF inhibitors have been used for years and remain the most established biologic class for this condition.

Examples include:

• Adalimumab
• Infliximab
• Etanercept
• Golimumab
• Certolizumab pegol

These medications have the longest track record in AS. For many patients, a TNF inhibitor is the first biologic a rheumatologist considers.

2. IL-17 inhibitors

These target interleukin-17, another inflammatory pathway involved in spondyloarthritis. They are especially important for people who cannot take a TNF inhibitor or who did not get enough benefit from one.

Examples include:

• Secukinumab
• Ixekizumab
• Bimekizumab

IL-17 inhibitors have expanded treatment options in a big way. That is good news, because AS treatment is rarely a one-size-fits-all situation. Bodies love being unique right when insurance paperwork is involved.

Which biologic is usually tried first?

In general, TNF inhibitors are often the preferred first biologic for active ankylosing spondylitis. That does not mean they are automatically the best choice for every person, but they tend to be the standard starting point because of their long history of use and strong evidence base.

If the first TNF inhibitor does not work, the next move often depends on how it failed:

• Primary nonresponse: The drug never really helps. In that case, switching to an IL-17 inhibitor may make more sense than trying a second TNF inhibitor.
• Secondary nonresponse: The drug worked for a while and then faded. In that case, another TNF inhibitor may still be a reasonable option.

That distinction matters more than many people realize. “This medication did not work” is useful. “It helped a lot for six months and then fizzled” is even more useful.

Can one biologic be better than another for certain symptoms?

Yes. Drug choice is not just about the spine. It can also be shaped by the other issues that travel with AS like uninvited houseguests.

For example:

• Recurrent uveitis: Some monoclonal TNF inhibitors are often preferred.
• Inflammatory bowel disease: Certain TNF inhibitors may be a better fit than IL-17 inhibitors, because IL-17 blockade can sometimes worsen or trigger IBD symptoms.
• Psoriasis: IL-17 inhibitors may be especially appealing if skin disease is also part of the picture.

This is why choosing a biologic should feel personalized. AS may affect the spine, but treatment decisions rarely stop there.

How well do biologics work?

When biologics work, they can make a meaningful difference. People may notice:

• Less morning stiffness
• Reduced inflammatory back pain
• Better sleep because pain is not waking them up
• Improved ability to exercise and move comfortably
• Less fatigue related to uncontrolled inflammation
• Better overall function and quality of life

That said, biologics are not magic wands. They do not erase every symptom overnight, and they do not reverse long-standing structural changes that have already happened. They are most helpful when they reduce active inflammation and make the disease more manageable over time.

How long do biologics take to work?

This is one of the most common questions, and the answer is frustratingly human: it depends.

Some people notice improvement within a few weeks. Others need a few months before the benefit becomes clear. TNF inhibitors often start showing results after a few doses, while the full benefit may take around three months. IL-17 inhibitors may also start helping within weeks, but full response can take several months.

The key point is this: one rough week after the first dose does not mean the medication has failed. AS treatment is often more slow-burn than fireworks.

How are biologics given?

Most biologics for ankylosing spondylitis are given either by self-injection under the skin or by intravenous infusion at a medical facility.

Depending on the drug, dosing may be:

• Weekly
• Every other week
• Monthly
• Every four to eight weeks after a starting phase

People often worry most about the delivery method before starting. That makes sense. Needles are not exactly a beloved hobby. But many patients find that once they learn the routine, the process becomes manageablemore annoying than terrifying, which is real progress.

Side effects and safety concerns

Because biologics calm parts of the immune system, the biggest safety issue is infection risk. That does not mean everyone on a biologic is constantly sick, but it does mean screening and monitoring matter.

Common or important safety issues include:

• Upper respiratory infections or other routine infections
• Injection-site reactions or infusion reactions
• Serious infections, including tuberculosis or fungal infections in some cases
• Need for hepatitis B screening in certain situations
• Holding treatment temporarily during a serious infection or around some surgeries

Some risks depend on the drug class.

TNF inhibitors can be associated with infections, rare neurologic issues, drug-induced lupus, worsening heart failure, and certain skin cancer concerns. They also require vaccine planning, especially because live vaccines are generally avoided during treatment.

IL-17 inhibitors can also raise infection risk, and they deserve extra caution in people with inflammatory bowel disease because they may worsen GI symptoms in some patients. Bimekizumab may also be linked with yeast infections such as oral or genital Candida in some people.

This is why starting a biologic usually comes with a checklist before the first dose. It is not bureaucracy for fun. It is how rheumatologists try to make a powerful medication safer.

What tests are needed before starting a biologic?

Before treatment begins, doctors commonly review:

• Tuberculosis screening
• Hepatitis B screening, especially for some biologics or risk profiles
• Vaccination status
• Recent infections or chronic infection history
• Other health conditions, including heart failure, neurologic disease, or inflammatory bowel disease
• Baseline labs when appropriate

With bimekizumab, liver-related lab checks may also be part of the pre-treatment evaluation. Your rheumatologist may also review pregnancy plans, travel, surgery timing, and whether you have frequent sinus, skin, or dental infections.

What about vaccines while taking biologics?

This is a big one. In general, you should talk with your rheumatology team before getting vaccinated. Many non-live vaccines are still used while someone is on biologic therapy, but live vaccines are often avoided during treatment.

That means planning ahead matters. It is much easier to sort out vaccine timing before the biologic starts than to realize later that your schedule, your immune system, and your travel plans have entered a complicated love triangle.

Are biosimilars an option?

Yes. Biosimilars are highly similar versions of already approved biologic medications. They are not generic drugs in the traditional sense, but they are designed to have no clinically meaningful differences in safety, purity, or effectiveness from the reference product.

In AS, biosimilars are especially relevant for some TNF inhibitors, particularly adalimumab and infliximab. For patients, the biggest practical advantage may be cost or insurance coverage. If your doctor recommends a biosimilar, the conversation is not about getting a “discount knockoff.” It is about using a regulated product designed to perform like the original.

What if the first biologic does not work?

That does not mean you are out of options. It usually means your rheumatologist will reassess the situation carefully.

They may ask:

• Was the medication given enough time?
• Was the disease truly active inflammatory AS, or is some pain now mechanical?
• Was there partial response that could still be meaningful?
• Did side effects, infections, or adherence issues interfere?
• Would switching to a different mechanism make more sense?

Sometimes the answer is another TNF inhibitor. Sometimes it is moving to an IL-17 inhibitor. The important thing is that a failed first biologic is a treatment detour, not the end of the road.

Biologics and everyday life

People often focus on the science of biologics, but daily life is where the medication has to prove itself. Can you sit through a movie? Walk the grocery store without plotting a mid-aisle nap? Get through a morning without feeling like your spine was assembled from rusty hinges?

These are not small outcomes. They are the entire point.

Many people on biologics build routines around dosing days, refill timing, refrigeration, lab work, and symptom tracking. That sounds tedious because, honestly, it can be. But good routines often make treatment less stressful and help patients spot whether a medication is really helping.

Questions to ask your rheumatologist

• Why are you recommending this biologic over other options?
• Am I a better candidate for a TNF inhibitor or an IL-17 inhibitor?
• How long should I try it before judging whether it works?
• What screenings or vaccines do I need first?
• What side effects should make me call right away?
• How will this choice affect uveitis, psoriasis, or gut symptoms if I have them?
• Is a biosimilar a reasonable option for me?

Experiences people often have with biologics for ankylosing spondylitis

One of the most common experiences is emotional whiplash at the beginning. Many people feel hopeful because they have heard biologics can be life-changing, but they are also nervous about side effects, infections, needles, and whether their insurance company is about to behave like a supervillain in business casual. All of that is normal. Starting a biologic is not just a medical decision. It feels personal, because it usually happens after months or years of pain, sleep disruption, and frustration.

Another common experience is that improvement can be surprisingly subtle at first. People sometimes expect a dramatic movie montage where they take one dose and suddenly sprint through a meadow. Real life is less theatrical. More often, someone realizes after a few weeks that they got out of bed a little faster, sat through dinner more comfortably, or made it through the afternoon without that heavy inflamed feeling. The progress can be gradual enough that family members notice it before the patient does.

There is also the practical learning curve. The first self-injection can feel intimidating, but many patients say the anticipation is worse than the shot itself. Others find infusions easier because they prefer having medical staff handle everything. Some people love the convenience of at-home dosing, while others would rather not keep medication in the refrigerator next to the yogurt and leftover takeout. It really comes down to lifestyle and comfort.

People also describe a period of trial and error. The first biologic may work beautifully, or it may help only halfway, or it may do almost nothing. That can be discouraging, but it is also common. Switching medications does not mean treatment has failed overall. It often means the matching process is still underway. Rheumatologists see this all the time, especially when symptoms are mixed with fatigue, muscle tension, old joint damage, or mechanical pain.

Another theme is that biologics often work best as part of a bigger plan. Patients who do well often still need exercise, stretching, physical therapy, sleep habits, stress management, and follow-up care. The medication may lower the inflammatory volume, but people still need to rebuild trust in movement. After living with pain for a long time, it can take a while to believe your body is not going to punish every attempt at activity.

Finally, many people say the biggest shift is not that they become symptom-free. It is that life becomes more predictable. They can plan mornings better, travel with less dread, and commit to work or family activities without constantly wondering whether their spine will sabotage the event. That kind of steadiness may not sound flashy, but for someone with AS, it can feel huge.

Conclusion

Biologics for ankylosing spondylitis are a major treatment option for people whose symptoms remain active despite first-line therapy. The two key biologic categories are TNF inhibitors and IL-17 inhibitors, and each comes with different strengths, tradeoffs, and practical considerations. The best choice depends on your symptom pattern, related conditions, infection risk, lifestyle, and response to previous treatment.

The bottom line is simple: biologics are not casual medications, but they can be genuinely transformative when used thoughtfully. If AS is making your world smaller, a well-chosen biologic may help open it back upone less-stiff morning at a time.